Blue Jet Healthcare waits for sustained margin recovery

The Blue Jet Healthcare Ltd stock is down almost 40% from its 52-week high of ₹1,027.80, seen on 21 July, a day before Q1FY26 results were announced-showing that its Ebitda margin fell to 34% from 41% in Q4FY25 due to inventory adjustments and a little product mix shuffle.

- Shubham Dilawari [e-mail]

Margins could well recover ahead, but investors will need proof before allocating brownie points. Within contract manufacturing, Blue Jet focuses on niche areas such as contrast media intermediates for diagnostic imaging, supplying major companies including GE Healthcare, Guerbet Group and Bracco Imaging.

It also produces high-intensity sweeteners, such as saccharin, for companies like Colgate-Palmolive and Unilever, along with other speciality pharmaceutical ingredients and Active Pharmaceutical Ingredients (APIs).